Rein Therapeutics
RNTX
23 hedge funds and large institutions have $1.15M invested in Rein Therapeutics in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.17% less ownership
Funds ownership: 0.64% → 0.46% (-0.17%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
72% less capital invested
Capital invested by funds: $4.03M → $1.15M (-$2.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$304K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$211K |
| 3 |
HBWM
Hollow Brook Wealth Management
Katonah,
New York
|
+$60.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$41.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$312K |
| 2 |
SLF
Sun Life Financial
Toronto,
Ontario, Canada
|
-$253K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$126K |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$83K |
| 5 |
Morgan Stanley
New York
|
-$82.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$12K | -218 | Closed |
|
RNTX Hedge Fund Activity: Q4 2018 in Review
23 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2018, worth a combined $1.15M — down 72% from $4.03M a quarter earlier.
Fund positioning in RNTX was balanced in Q4 2018: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $304K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $312K sold.
- 23 institutional investors held Rein Therapeutics (RNTX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $1.15M of Rein Therapeutics stock for Q4 2018, down 72% quarter-over-quarter.
- 6 funds opened new Rein Therapeutics positions in Q4 2018 and 6 closed out, a net change of 0 holders.
- The largest Rein Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $304K added.
- The largest Rein Therapeutics seller in Q4 2018 was Bridgeway Capital Management, an estimated $312K sold.
Based on aggregated 13F filings for Q4 2018.